Catastrophism in Chronic Inflammatory Rheumatism

Chronic Inflammatory Rheumatism Clinical Trial

— CRIC  

Official title:

Catastrophism in Chronic Inflammatory Rheumatism

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04174092
• Other study ID #: LOCAL 2019/CGV/01
• Secondary ID: 2019.A01715-52
• Status: Completed
• Phase: N/A
• Start date: October 27, 2019
• Est. completion date: December 17, 2022

Study information

• Verified date: March 2023
• Source: Centre Hospitalier Universitaire de Nimes
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Catastrophic is defined as a negative cognitive and emotional response based on inadequate pain expression. It has three components: rumination, amplification and vulnerability. The assessment of catastrophism is carried out using a validated questionnaire called the "Pain Catatrophizing Scale" (PCS). Recent studies highlight the significant impact of catastrophism in neuromuscular and mechanical rheumatic diseases such as gonarthrosis gonalgia and low back pain. In these diseases, it has been shown that catastrophism has a negative impact both on the experience of pain and on the response to different types of treatments (medical and surgical). Several studies have implemented multidisciplinary management and in particular cognitive-behavioural therapy with an improvement in the pain experience in patients who are catastrophic. In chronic inflammatory rheumatic diseases such as rheumatoid arthritis, spondyloarthritis and psoriatic arthritis, the prevalence and impact of catastrophism is still poorly understood.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 533
• Est. completion date: December 17, 2022
• Est. primary completion date: December 17, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Major patients, hospital follow-up, with RA according to ACR 2010 criteria, or spondyloarthritis according to ASAS 2009 criteria or according to AMOR or psoriatic arthritis according to Caspar 2006 criteria.
• Patient who has given free and informed consent.
• Patient who has signed the consent form.
• Patient affiliated or benefiting from a health insurance plan.
• Adult patient (=18 years old).

Exclusion Criteria:

• Patient under the protection of justice, under guardianship or curatorship.
• Patient unable to express consent.
• Patient for whom it is impossible to provide informed information.
• Poor command and understanding of the French language making it impossible to complete self-questionnaires

Related Conditions & MeSH terms

• Chronic Inflammatory Rheumatism
• Collagen Diseases
• Rheumatic Diseases
• Rheumatic Fever

Intervention

Other:
• completing self-questionnaires
completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism

Locations

Country	Name	City	State
France	CHU de Montpellier	Montpellier
France	CHU de Nîmes	Nîmes

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	catastrophic assessment	Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism)	Day 0
Primary	catastrophic assessment	Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism)	at 3 months
Primary	catastrophic assessment	Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism)	at 6 months
Primary	catastrophic assessment	Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism)	at 12 months